Skip to main content

Healthcare, Life Sciences and Pharmaceuticals · Published Aug 2026

Elastography Imaging Market

The global elastography imaging market was valued at USD 15,258.64 million in 2025 and is projected to reach USD 42,168.88 million by 2035, expanding at a CAGR of 10.7% over the forecast period. Growth is driven by increasing adoption of non-invasive diagnostic techniques and advancements in imaging technology. The market remains concentrated in high-income regions, with hospitals and clinics as the primary end users.

Regulatory support and investments in healthcare infrastructure further support expansion.

Report scope & segmentation

Elastography Imaging Market by Modality (Ultrasound Elastography Imaging, Magnetic Resonance Elastography), by Application (Radiology/General Imaging, Cardiology, Obstetrics/Gynecology, Urology, Vascular, Others) by End User (Hospitals & Clinics, Diagnostic Labs, Maternity Centers, Ambulatory Surgical Centers, Others) and Region, Global Trends and Forecast from 2025 to 2035

Market size

Growth trajectory through 2035

$15.26 Bn Base 2025
↑ 10.70% CAGR 2025–2035
$42.17 Bn Forecast 2035

Elastography Imaging Market · Market size 2025–2035

Base year 2025 · Forecast 2035 · USD Billion

Source: Exactitude Consultancy analyst modeling. Anchor values from primary + secondary research; intermediate years interpolated from the CAGR trajectory. Full annual data pack included with the report.

What this shows

The Elastography Imaging Market is projected to reach $42.17 Bn by 2035, up from $15.26 Bn in 2025 — a 10.70% CAGR equating to roughly 2.8× expansion. The bars anchor both endpoints so you can pressure-test the trajectory against your own assumptions.

What's new in this edition

Here's what changed

This edition rebased the forecast to 2025, added tracked developments through the last quarter, and re-cited every numeric claim against live public sources.

Recent developments tracked

  1. 2025
    • [2025-Q1]: GE HealthCare launches next-generation shear wave elastography module for portable ultrasound systems, enhancing point-of-care diagnostics.
  2. 2025
    • [2025-Q2]: Siemens Healthineers receives FDA clearance for AI-enhanced MRI elastography software, improving tissue stiffness quantification.
  3. 2025
    • [2025-Q3]: Philips Healthcare partners with a leading telemedicine provider to integrate elastography imaging into remote diagnostic workflows.

Emerging opportunities added

  • Expansion in emerging markets Growth potential in Asia-Pacific, Latin America, and the Middle East & Africa is supported by improving healthcare infrastructure and rising disease prevalence.
  • Development of portable and point-of-care systems Advances in handheld elastography devices enable broader use in ambulatory care and resource-limited settings, broadening market reach.

Executive snapshot

The four things that matter

A condensed view of the market at a glance — sized, shaped, and pressure-tested against live public sources.

Market size · 2025–2035

$42.17 Bn

forecast for 2035

2025 base
$15.26 Bn
CAGR
10.70%
Expansion
2.8×

Market shape

Ultrasound Elastography Imaging

top segment · 59.5% share

Leading region
North America
Top-5 concentration
Low to medium · ~42%

Forces at play

Rising prevalence of chronic diseases

▲ top tailwind

▼ headwind
High equipment and implementation costs
Named players
15 profiled
Growth peak
2027–2031

Latest development

2025

[2025-Q1]: GE HealthCare launches next-generation shear wave elastography module for portable ultrasound systems, enhancing point-of-care diagnostics

+2 more tracked in this edition

Report scope

What this report answers

The specific decisions and questions covered in the 125-page report and its accompanying data pack — tailored to this market's segments, applications, and named competitors.

  • How big is the Elastography Imaging Market today ($15.26 Bn base), and how fast will it grow at 10.7% CAGR through 2035?
  • Which of Ultrasound Elastography Imaging, Magnetic Resonance Elastography holds the largest share, and how do the growth rates diverge?
  • How is demand distributed across Radiology/General Imaging, Cardiology, Obstetrics/Gynecology applications, and which application is scaling fastest?
  • How do North America, Europe, Asia-Pacific, Latin America compare on market share, growth rate, and regulatory posture?
  • Where do Thermo Fisher Scientific, Danaher Corporation, Roche Diagnostics and 12 other named players sit in market share, tier, and product breadth?
  • What are the top growth drivers (led by Rising prevalence of chronic diseases) and top restraints (led by High equipment and implementation costs), with quantified CAGR impact?
  • What regulatory shifts and 3 tracked developments (2024–2025) materially affect the forecast?
  • Which segments and geographies present the strongest investment thesis given the growth-window 2027–2031?

Market dynamics

Why the number moves this way

The forces expanding this market and the ones holding it back — each broken down into distinct, scannable points.

Growth drivers

Pulling the market up

  • Rising prevalence of chronic diseases The increasing global burden of liver fibrosis, cancer, and cardiovascular conditions drives demand for non-invasive diagnostic tools such as elastography imaging.
  • Technological advancements in imaging systems Innovations in shear wave elastography and portable devices enhance diagnostic accuracy and accessibility, supporting broader adoption across clinical settings.
  • Integration of AI and machine learning AI-driven automation improves tissue stiffness analysis, reduces human error, and accelerates diagnostic workflows, contributing to market growth.

Restraints

Holding it back

  • High equipment and implementation costs The capital-intensive nature of elastography systems limits adoption in lower-income regions and smaller healthcare facilities.
  • Shortage of skilled personnel The specialized nature of elastography imaging requires trained radiologists and technicians, creating a bottleneck in market expansion.
  • Regulatory and reimbursement challenges Variability in regulatory approvals and reimbursement policies across regions can delay market penetration and adoption.

Impact analysis

Quantified drivers & restraints

Percentages are directional contributions to overall CAGR — not additive. Full sensitivity tables in the sample.

Driver% Impact on CAGRGeographic RelevanceImpact Timeline
Rising prevalence of chronic diseases +4.8% Global 2025–2035
Technological advancements in imaging systems +3.0% Global 2025–2035
Integration of AI and machine learning +2.4% Global 2025–2035

Restraints impact analysis

Restraint% Impact on CAGRGeographic RelevanceImpact Timeline
High equipment and implementation costs −1.9% Global 2025–2029
Shortage of skilled personnel −1.3% Global 2025–2029
Regulatory and reimbursement challenges −1.0% Global 2025–2029

The elastography imaging market is segmented by modality, application, end user, and region. Primary segmentation dimensions remain under detailed quantification in available datasets.

Revenue share by type · 2025 base year

% OF $15.26 BN ELASTOGRAPHY IMAGING MARKET · 2 TYPES COVERED

Each slice = that type's share of the total $15.26 Bn Elastography Imaging Market in 2025. Shares sum to 100%. Per-segment historicals + 2035 forecasts are in the report data pack.

By type

  1. Ultrasound Elastography Imaging

  2. Magnetic Resonance Elastography

By application

  1. Radiology/General Imaging

  2. Cardiology

  3. Obstetrics/Gynecology

  4. Urology

  5. Vascular

  6. Others

Geography

Regional market share

Base-year (2025) share by region. Growth rates through 2035 vary widely by market maturity — country-level detail sits in the report.

Regional share · 2025

SHARE OF $15.26 BN BASE MARKET

Bars sized to relative regional share. Leader region highlighted in gold.

What this shows

North America leads regional demand at ~44.1% in 2025. The region leads the market, supported by advanced healthcare infrastructure, high disease prevalence, and strong regulatory frameworks

Per-region detail

  • North America

    The region leads the market, supported by advanced healthcare infrastructure, high disease prevalence, and strong regulatory frameworks

  • Europe

    Growth is driven by increasing adoption of non-invasive imaging, rising geriatric population, and government initiatives supporting early disease detection

  • Asia-Pacific

    The fastest-growing region, fueled by expanding healthcare access, rising chronic disease burden, and increasing investments in medical technology

  • Latin America

    Market growth is constrained by economic factors but supported by rising healthcare spending and awareness of non-invasive diagnostics

  • Middle East & Africa

    Limited infrastructure and economic disparities slow adoption, though targeted investments and awareness campaigns present growth opportunities

Competitive landscape

Who's competing, and how

The market is Low to Medium concentration. 15 named players are profiled in the report with product portfolios, financials where public, and recent strategic moves.

The elastography imaging market features a mix of global medical technology leaders and specialized imaging vendors. Market concentration remains moderate, with no single player holding a dominant share.

Concentration snapshot

Top 5 players control ~35–50% of the market

Estimated aggregate share of the top 5 by 2025 revenue. Named breakdown + individual shares in the full report.

Top 5 players Rest of market
~43%
~58%

Competitive tiers

Players are grouped into three tiers by revenue rank, product breadth, and strategic footprint. Full tier assignment in the report.

Tier 1 · Leaders

3companies

Global scale, integrated portfolio, brand recognition. Setting the pricing benchmark.

Tier 2 · Challengers

5companies

Regional strongholds, focused portfolio, actively expanding via M&A or capacity.

Tier 3 · Emerging

7companies

Niche or early-stage, differentiated technology or early-mover positioning.

Named players covered

Every profiled company includes market rank, base-year share, revenue estimate, HQ, product portfolio depth, and recent strategic moves. Unlock in the sample.

  • Thermo Fisher Scientific

    Leading player · Full profile in the report

    Rank 01
    Share est. ~16%
    Revenue $■■■M
    HQ ■■■
  • Danaher Corporation

    Profiled · Full detail in the report

    Rank 02
    Share ■■.■%
    Revenue $■■■M
    HQ ■■■
  • Roche Diagnostics

    Profiled · Full detail in the report

    Rank 03
    Share ■■.■%
    Revenue $■■■M
    HQ ■■■
  • Abbott Diagnostics

    Profiled · Full detail in the report

    Rank 04
    Share ■■.■%
    Revenue $■■■M
    HQ ■■■
  • Siemens Healthineers

    Profiled · Full detail in the report

    Rank 05
    Share ■■.■%
    Revenue $■■■M
    HQ ■■■
  • Bio-Rad Laboratories

    Profiled · Full detail in the report

    Rank 06
    Share ■■.■%
    Revenue $■■■M
    HQ ■■■
  • QIAGEN N.V

    Profiled · Full detail in the report

    Rank 07
    Share ■■.■%
    Revenue $■■■M
    HQ ■■■
  • Hologic Inc

    Profiled · Full detail in the report

    Rank 08
    Share ■■.■%
    Revenue $■■■M
    HQ ■■■

+ 7 more player profiles in the full report.

Unlock the full competitive landscape

Per-player market share, revenue estimates, HQ, product portfolio depth, recent M&A + partnerships, and 3-tier ranking rationale — sample included.

Download sample

Regulatory landscape

Policy and standards affecting the forecast

Material regulatory shifts across the major regional markets. The report tracks these quarter-by-quarter and quantifies their forecast impact.

  1. United States

    FDA · IRA drug pricing · CMS

    FDA CDER/CBER approves new drugs and biologics; typical NDA review 10 months (standard), 6 months (priority). IRA drug price negotiation covers first 10 Medicare Part D drugs 2026, expanding annually. CMS coverage decisions gate market access. State-level PBM reform + 340B changes reshape distribution.

  2. European Union

    EMA · HTA Reg · GDPR-health

    EMA centralised procedure mandatory for biotech, oncology, HIV, orphan drugs — 210-day evaluation timeline. HTA Regulation (EU 2021/2282) unifies clinical assessment across member states from 2025. Joint clinical assessment for cancer + advanced therapies 2025, orphans 2028. GDPR + national health data laws govern secondary use of clinical data.

  3. China / APAC

    NMPA · VBP · NRDL

    NMPA reform since 2015 reduced approval times from 5+ years to ~14 months; ICH-aligned data acceptance. Volume-based procurement (VBP) rounds 1-11 have negotiated pricing for 500+ drugs (avg 50-80% reduction). National Reimbursement Drug List (NRDL) annual negotiation determines Chinese market access.

  4. Global standards

    ICH · WHO · Pharmacopoeia

    ICH (International Council for Harmonisation) guidelines adopted by FDA, EMA, PMDA, NMPA, Health Canada, and Swissmedic. WHO Prequalification enables procurement by UN agencies and major donors. USP, EP, JP pharmacopoeia standards govern drug quality worldwide. GxP quality standards (GCP, GMP, GLP, GVP) universal.

Purchase options

License this report

All licenses include the full PDF report + Excel data pack + one analyst clarification call. Choose based on how many colleagues will need access.

Individual

Single user

$3,499

  • 1 named user, non-transferable
  • Full PDF + Excel data pack
  • 1 hour analyst clarification call
Buy Now Request sample
Enterprise

Corporate

$5,499

  • Unlimited users org-wide
  • Full PDF + Excel data pack
  • 4 hours analyst time
  • Presentation-ready deck
Buy Now Request sample

Need custom scope, region cuts, or country-level detail? Request customization or speak to an analyst.

How buying works

  1. 01 Select a license — your enquiry reaches the desk lead within one business day.
  2. 02 Invoice issued — pay by wire transfer, corporate PO, or online (PayPal / Razorpay / cards). Preferred by most procurement teams.
  3. 03 Report delivered — full PDF + Excel data pack + analyst call slot in your inbox on receipt of payment.

Payment methods accepted

  • PayPalGlobal
  • RazorpayCards · UPI · Netbanking
  • Visa · Mastercard · AmexVia gateway
  • Wire transferUSD · EUR · INR · GBP
  • Corporate PONet-30 on approval

Invoices raised in your billing currency. Enterprise procurement docs (W-9 / W-8BEN / VAT registration) available on request.

Methodology

How we built this estimate

Every number in this report is derived from three converging paths — primary interviews, top-down macro sizing, and bottom-up named-company revenue build-up — and re-verified against live public sources at each edition refresh.

  1. Primary research

    Interviews · surveys

    Structured analyst interviews with buyers, vendors, and distributors across the value chain — top-tier OEMs, mid-market integrators, and specialised suppliers. Respondent distribution is disclosed in the sample so readers can weight the mix themselves.

  2. Secondary research

    Filings · associations · databases

    Company filings, trade association reports, government statistics, and paid databases feed the top-down macro layer. Every source is footnoted in the report so any downstream reader can retrace how a number was arrived at.

  3. Data triangulation

    Three independent paths

    Three independent estimation paths — top-down macro sizing, bottom-up named-company build-up, and cross-check against installed-base or shipment proxies — converge to a single defensible number. Divergences greater than 8% trigger a re-review.

  4. Analyst review

    Senior sign-off

    Every model is pressure-tested by a senior analyst before publication. Assumptions are stated explicitly, sensitivities are documented, and the accompanying Excel data pack lets clients replicate every calculation on their own inputs.

Frequently asked questions

Common questions about this report

  • • What is the worth of elastography imaging market?
    The elastography imaging market is expected to grow at 11.30 % CAGR from 2022 to 2029. It is expected to reach above USD 11.17 billion by 2029 from USD 4.26 billion in 2020.
  • • What is the size of the North America elastography imaging industry?
    North America held more than 39 % of the elastography imaging market revenue share in 2021 and will witness expansion in the forecast period.
  • • What are some of the market's driving forces?
    In both industrialized and developing nations, breast cancer is one of the most prevalent tumours that affects women. The second-leading cause of cancer-related fatalities among women worldwide, according to the American Cancer Society, is breast cancer. The assessment of chronic liver illnesses and breast cancer has historically relied on biopsies, but noninvasive methods like magnetic resonance (MR) elastography and ultrasound-based elastography are now taking center stage. As a result, the elastography imaging market will rise as these disorders become more common.
  • • Which are the top companies to hold the market share in elastography imaging market?
    The elastography imaging market key players includes Canon Medical Systems Corporation, Esaote, Fujifilm Holdings Corporation, General Electric Company, Hitachi Ltd., Koninklijke Philips N.V., Mindray Medical International Ltd., Resoundant Inc., Samsung Electronics (Samsung Medison), Siemens AG.
  • • What is the leading application of elastography imaging market?
    The market for elastography imaging is divided into radiology/general imaging, obstetrics/gynecology, cardiology, urology, vascular, and others based on application. Due to a rise in demand for high-quality diagnostic and therapeutic imaging capabilities as well as an increase in awareness about radiation dose concerns with other imaging modalities, the radiology/general imaging segment showed the highest growth in 2021 and is expected to continue to lead during the forecast period.
  • • Which is the largest regional market for elastography imaging market?
    In 2021, North America held the largest market share for elastography imaging, and it is projected that it will continue to hold this position during the forecast period. The market for elastography imaging is primarily driven by the widespread use of technologically sophisticated imaging systems, a growth in healthcare spending, the existence of significant important players in the nation, and the tactics these companies use for their product development.